NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Other Prepaid Expenses and Other Current Assets

9 Months Ended

Jun. 30, 2021

5. Other Prepaid Expenses and Other Current Assets

The Company’s prepaid expenses and other current assets consisted of the following:


	As of June 30,		As of September 30,
	2021		2020
Prepaid research and development expense	$	308,490	$	205,641
Prepaid rent		285,577		—
Other prepaid expenses and other current assets		75,074		88,999
Total	$	669,141	$	294,640